Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Eton Pharmaceuticals' Share-based Compensation rose 5124.65% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 6501.76%. This contributed to the annual value of $3.2 million for FY2024, which is 89.26% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Share-based Compensation of $1.1 million as of Q3 2025, which was up 5124.65% from $2.1 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Share-based Compensation high stood at $2.1 million for Q2 2025, and its period low was $673000.0 during Q1 2021.
  • Over the past 5 years, Eton Pharmaceuticals' median Share-based Compensation value was $863000.0 (recorded in 2021), while the average stood at $962578.9.
  • In the last 5 years, Eton Pharmaceuticals' Share-based Compensation crashed by 3961.54% in 2023 and then surged by 14952.38% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Share-based Compensation (Quarter) stood at $863000.0 in 2021, then grew by 2.67% to $886000.0 in 2022, then decreased by 15.35% to $750000.0 in 2023, then increased by 4.27% to $782000.0 in 2024, then surged by 39.64% to $1.1 million in 2025.
  • Its Share-based Compensation stands at $1.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $1.2 million for Q1 2025.